In a high-stakes ruling that expands presidential authority over independent federal agencies, the U.S. Supreme Court had one ...

Tucker Carlson agreed that Trump's Middle East business deals "seem like corruption" after his administration secured massive AI and defense agreements with the same countries, reigniting ...

Trump revokes Harvard's ability to enroll international students, accusing the university of fostering violence and ...

Founded by University of Washington computer science professor Shyam Gollakota and PhD student Malek Itani, Hearvana is ...

Jamie Dimon says the U.S. can’t take its status as the world’s top economic power for granted anymore.

Shares of IonQ Inc. (NYSE: IONQ) soared on Thursday after CEO Niccolo de Masi made bold statements comparing the company's ...

If you've ever joked that Bill Gates might be behind your fries, it turns out that punchline isn't too far off. While ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $36.67, a high estimate of $40.00, and a low estimate of $35.00. Observing a 5.28% ...

Peabody is a story of value waiting to be rediscovered. For those willing to dig a little bit deeper, this coal giant is a ...

Bitcoin‘s (CRYPTO: BTC) recent surge to an all-time high of $111,900 has reignited discussions about its market dominance and ...

Las acciones de HIMS caen tras la prohibición de la FDA sobre versiones elaboradas de semaglutide, clave para su negocio de ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.